Pathstone Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $4.68M | Buy |
5,649
+2,383
| +73% | +$1.98M | 0.04% | 283 |
|
|
2023
Q2 | $2.32M | Buy |
3,266
+100
| +3% | +$71.1K | 0.03% | 294 |
|
|
2023
Q1 | $2.64M | Sell |
3,166
-5,470
| -63% | -$4.56M | 0.04% | 246 |
|
|
2022
Q4 | $5.84M | Buy |
8,636
+1,234
| +17% | +$834K | 0.05% | 257 |
|
|
2022
Q3 | $5.15M | Buy |
7,402
+6,249
| +542% | +$4.35M | 0.05% | 226 |
|
|
2022
Q2 | $681K | Buy |
1,153
+40
| +4% | +$23.6K | 0.02% | 459 |
|
|
2022
Q1 | $802K | Buy |
1,113
+85
| +8% | +$61.2K | 0.02% | 391 |
|
|
2021
Q4 | $649K | Buy |
1,028
+552
| +116% | +$348K | 0.02% | 455 |
|
|
2021
Q3 | $288K | Sell |
476
-35
| -7% | -$21.2K | 0.01% | 690 |
|
|
2021
Q2 | $285K | Buy |
511
+6
| +1% | +$3.35K | 0.01% | 662 |
|
|
2021
Q1 | $239K | Buy |
505
+161
| +47% | +$76.2K | 0.01% | 553 |
|
|
2020
Q4 | $166K | Buy |
344
+242
| +237% | +$117K | 0.01% | 285 |
|
|
2020
Q3 | $57K | Hold |
102
| – | – | 0.01% | 352 |
|
|
2020
Q2 | $63K | Sell |
102
-20
| -16% | -$12.4K | 0.01% | 283 |
|
|
2020
Q1 | $60K | Sell |
122
-16
| -12% | -$7.87K | 0.01% | 276 |
|
|
2019
Q4 | $518K | Buy |
138
+38
| +38% | +$143K | 0.01% | 290 |
|
|
2019
Q3 | $28K | Hold |
100
| – | – | ﹤0.01% | 353 |
|
|
2019
Q2 | $31K | Sell |
100
-21
| -17% | -$6.51K | ﹤0.01% | 386 |
|
|
2019
Q1 | $50K | Buy |
121
+100
| +476% | +$41.3K | 0.01% | 305 |
|
|
2018
Q4 | $8K | Buy |
+21
| New | +$8K | ﹤0.01% | 345 |
|
|
2017
Q2 | – | Sell |
-3
| Closed | -$1K | – | 592 |
|
|
2017
Q1 | $1K | Buy |
+3
| New | +$1K | ﹤0.01% | 506 |
|
|
2013
Q3 | – | Sell |
-47
| Closed | -$11K | – | 401 |
|
|
2013
Q2 | $11K | Buy |
+47
| New | +$11K | 0.01% | 236 |
|